Last reviewed · How we verify
NCT05715450
Falciformopexy for Treatment Perforated Peptic Ulcer.
NA trial testing Falciformopexy for Treatment Perforated Peptic Ulcer in Perforated Peptic Ulcer in 25 participants. Not yet recruiting.
23 October 2026
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 30 May 2023 |
| Primary completion | 23 October 2026 |
| Estimated completion | 23 November 2026 |
Drugs / interventions tested
- Falciformopexy for Treatment Perforated Peptic Ulcer
Conditions studied
- Perforated Peptic Ulcer — all drugs for Perforated Peptic Ulcer →
Sponsor
Assiut University
Who can join
Adults 18 to 70, any sex, with Perforated Peptic Ulcer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Use the falciform ligament flap for the treatment of perforated peptic ulcer
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05715450
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Perforated Peptic Ulcer
Currently open trials in the same condition.
- NCT06550856 — SUTURE-CLOSURE OMENTOPEXY VERSUS OMENTOPEXY ALONE IN REPAIR OF PERFORATED PEPTIC ULCER · NA · recruiting
- NCT06484699 — Open Versus Laparoscopic Repair of Perforated Peptic Ulcer · NA · recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05715450 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 10 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05715450.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing